Breast Cancer Clinical Trial

Triple Negative Breast Cancer Biomarker Study

Summary

Patients with metastatic or locally recurrent triple negative breast cancer (TNBC) who are scheduled for medically indicated surgical biopsy or resection of disease will be identified. Fresh/frozen tissue will be collected and will undergo comprehensive molecular evaluation with NextGen sequencing. TGEN's clonal genomics analyses will be applied in the analysis to identify and prioritize the mutated targets. Therapeutic options, based on the genetic profile of each patient's tumor, will be discussed and an appropriate molecularly-selected agent will be recommended by the Study Investigator(s) (SI) and treating oncologist as treatment for the patient.

This is an open-label, pilot trial. Patients with metastatic or locally recurrent TNBC who are scheduled for medically indicated surgical biopsy or resection will be enrolled and therapeutic options, based on the genetic profile of each patient's tumor, will be discussed with the patient.

Time-to-progression (TTP) for these patients following the selected therapy is the primary objective and will be compared to the TTP(s) for their most recent prior therapy. A 30% increase in TTP with the molecularly-targeted agent compared with the TTP on the immediate prior therapy will be considered as evidence of clinical benefit from the selected therapy. The secondary endpoints are best response to the molecularly-selected therapy, overall survival (OS) and genetic mutation evaluation in metastatic (or locally recurrent) TNBC.

The study is designed to demonstrate that the collection and analysis of these tumor samples is feasible.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has metastatic or locally recurrent triple negative breast cancer and is scheduled for medically indicated surgical biopsy or resection of disease
Will have measurable or evaluable (nonmeasurable) disease per RECIST v 1.1 (see Section 10) present after surgical biopsy/resection. Note: following surgical resection, if the tumor sample is found to be inadequate for comprehensive molecular analysis, the patient will be deemed ineligible and will be replaced.
Has received at least 1 prior chemotherapeutic regimen for their metastatic or locally recurrent TNBC prior to initiating the molecularly-selected therapy. There is no limit on the prior therapy for TNBC. Note: We strongly recommend holding of on intervening therapy if possible from the time of biopsy to the completion of sequencing so as not to change the cancer under the selective pressure of treatment, so that the sequencing results are reflective of the current cancer.
Is at least 18 years of age
Has an expected survival of at least 6 months, as estimated by the treating oncologist
Has planned surgical resection (indicated for the medical care of the patient) that will yield a minimum fresh/frozen tumor sample of 1 cm x 1 cm x 1 cm (~300 mg) that will be available for molecular profiling analysis.
Is agreeable to having a blood sample (10-20 mL) drawn and analyzed to compare their normal genetic profile to that of their tumor sample
Has signed the most recent Patient Informed Consent Form
Has signed a Patient Authorization Form

Exclusion Criteria:

Has breast cancer other than metastatic or locally recurrent TNBC. Note: surgical resection of the recurrent TNBC will render the patient as "no evidence of disease" (NED). NED patients are ineligible and will be replaced.
Has a history of heart disease, other conditions that would prevent treatment with a standard chemotherapeutic agent
Has evidence of central nervous system (CNS) involvement that is progressing or that requires radiation, resection or steroid therapy
Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
Is a pregnant or nursing woman
Is unable to comply with requirements of study

Study is for people with:

Breast Cancer

Estimated Enrollment:

14

Study ID:

NCT01111175

Recruitment Status:

Completed

Sponsor:

US Oncology Research

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 18 Locations for this study

See Locations Near You

Rocky Mountain Cancer Centers
Denver Colorado, 80220, United States
Virginia Oncology Assocites
Elizabeth City North Carolina, 27909, United States
Northwest Cancer Specialists, P.C.
Portland Oregon, 97213, United States
Northwest Cancer Specialists, P.C.
Portland Oregon, 97225, United States
Northwest Cancer Specialists, P.C.
Portland Oregon, 97227, United States
Northwest Cancer Specialists, P.C.
Tualatin Oregon, 97062, United States
Texas Oncology-Dallas Presbyterian Hospital
Dallas Texas, 75231, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas Texas, 75246, United States
Texas Oncology-Memorial City
Houston Texas, 77024, United States
Texas Oncology - Tyler
Tyler Texas, 75702, United States
Virginia Oncology Associates
Chesapeake Virginia, 23320, United States
Virginia Oncology Associates
Hampton Virginia, 23666, United States
Virginia Oncology Associates
Newport News Virginia, 23606, United States
Virginia Oncology Associates
Norfolk Virginia, 23502, United States
Virginia Oncology Associates
Virginia Beach Virginia, 23456, United States
Virginia Oncology Associates
Williamsburg Virginia, 23188, United States
Northwest Cancer Specialists, P.C.
Vancouver Washington, 98684, United States
Northwest Cancer Specialists, P.C.
Vancouver Washington, 98686, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

14

Study ID:

NCT01111175

Recruitment Status:

Completed

Sponsor:


US Oncology Research

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider